Royce Premier Fund gained 5.6% in 2025, lagging its small-cap benchmark. Read the full analysis for more details.
Regenxbio (RGNX) hit by FDA CRL for RGX-121; valuation discount, cash runway to 2027, risks vs RGX-202 upside. Click here to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果